Director, Cellular Therapeutics; Associate Chair, Junior Faculty Development, Department of Medicine Memorial Sloan-Kettering Cancer Center
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen. These latter projects are similarly in the process of translation to the clinical setting.
Director Translational Development, Cellular Therapeutics Center; Assistant Attending, Myeloma Service
Memorial Sloan Kettering Cancer Center
Dr. Eric Smith received his MD, PhD and internal medicine training at Mount Sinai School of Medicine/Mount Sinai Hospital and oncology training at Memorial Sloan Kettering Cancer Center both in New York, NY where he remained on as faculty and serves as an Assistant Attending on the Myeloma Service and the Director of Translational Development in the Cellular Therapeutics Center there.
His research resulted in the development of human derived chimeric antigen receptor (CAR) vectors for the treatment of advanced myeloma, which are under clinical investigation in 4 independent trials, including a multi-institution phase I/II. Currently, his research focuses on understanding how the myeloma microenvironment influences CAR T cell biology and function in patients and mice, and generating rational next generation CAR constructs with enhanced efficacy for the treatment of myeloma. Research funding has been awarded for his work from a MSK Technology Development Fund, the Multiple Myeloma Research Foundation (MMRF), the Lymphoma Research Foundation (LRF), the American Society of Clinical Oncology (ASCO), the Society for Immunotherapy of Cancer (SITC), the American Society of Hematology (ASH), and the Leukemia and Lymphoma Society (LLS).
Director-Stem Cell Transplantation St George’s Hospital and Medical School Medical Director
Cell Therapy Programme Health Sciences Authority, Singapore
Dr Mickey Koh received his medical degree in Singapore and all his subsequent specialist Haematology training including his FRCPath, MRCP and PhD in London.
He holds several joint positions. Dr Koh is a Consultant Haematologist and Senior Lecturer at St George’s Hospital and Medical School, London, UK. He is also the Programme Director of the Stem Cell Transplant Programme as well as being the Clinical Lead for Bone Marrow Failures and Rare Haematological Diseases at St George’s Hospital.
At the same time, he is also the Programme Director of the Cell Therapy Facility in Singapore involved in cell therapy trials cross haemato-oncology and regenerative medicine. He was also previously the Deputy Director of the National Blood Service in Singapore
Dr Koh sits on the board of various transplant and cell therapy organizations including being the Chairperson of the Cell Therapy Working Party at International Society Blood Transfusion and Chairperson of the Graft Processing/Cellular Therapies subcommittee of Worldwide Network for Blood and Marrow Transplantation. He is a past Board member of the International Society of Cellular Therapy Therapy and is Vice President of the ISCT presidential Task force on Unproven therapies. Dr Koh has also been an advisor to the World Health Organisation on matters of transfusion and cellular therapies. He is widely published and is also on the editorial board of various peer reveiwed journals
Professor of Medicinal Chemistry
Monash Institute of Pharmaceutical Sciences (MIPS) Monash University
Prof. Jonathan Baell, Ph.D is a Larkins Fellow, Director of the Australian Translational Medicinal Chemistry Facility and an NHMRC Principal Research Fellow, at Monash Institute of Pharmaceutical Sciences (MIPS). He obtained his PhD in 1992 under Professors Peter Andrews and Paul Alewood. Then he obtained a senior position in Australia’s prestigious National Scientific Organisation, CSIRO, where later at the age of 28 he became CSIRO’s youngest Senior Research Scientist. After a decade as Head of Medicinal Chemistry at Australia’s Premier Medical Research Institute, WEHI, he was appointed as a research professor at MIPS, which in 2017 and 2018 was ranked #2 in the world for Pharmacy and Pharmacology (QS World University Rankings). His interests are in the design of quality of HTS libraries, medicinal chemistry hit-to-lead and lead optimization, and computer-aided peptidomimetic design in order to generate compounds with potential therapeutic utility and of value. He has papers in Nature, Nature Communications, Nature Chemical Biology and Journal of Medicinal Chemistry (15) and over 40 granted pharmaceutical patents making key contributions to a number of compounds in various stages of development, from preclinical to one currently in phase I clinical trials for anxiolysis, and has consulted widely for the Australian Biotechnology Industry. In 2005 he was awarded the 2004 Biota Medal, a National Award for Excellence in Medicinal Chemistry for an early to mid-career researcher. This was followed recently with the 2018 Adrien Albert Award, Australia’s most prestigious award for sustained medicinal chemistry excellence. His 2010 HTS publication on Pan Assay Interference Compounds, or PAINS, and has been most highly cited primary research article in the Journal of Medicinal Chemistry over a 3-year period, currently tracking at more than 1200 citations. He sits on numerous scientific and editorial advisory boards, including Journal of Medicinal Chemistry, and is Senior Editor of Future Medicinal Chemistry
Peihua ( Peggy ) Lu
Medical Executive President Lu Daopei Hosptial and Lu Daopei Institute of Hematology
Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA.
She completed her hematology and oncology fellowship at Stanford University
• American Board Certified Hematologist & Oncologist, with American and Chinese Medical License.
• Member of ASH，ASCO & CAHON
• Chairman of Hematology Specialty Committee of Chinese Non-government Medical Institutions Association (CNMIA)
• Member of Chinese Marrow Donor Program(CMDP) Expert Committee
• Member of Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Expert Committee
• Member of the Hematology Translational Medicine Committee of China Anti-Cancer Association（CACA）
• Vice Chairman of Sanhe Private Hospital Industry Association
• She has had many awards which including National Cancer Institute individual fellowship award, physician scientist award (K011)
Chief Technology Officer Mustang Bio
Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
Philip G. Vanek
GM, Cell and Gene Therapy Strategy GE Healthcare
Philip G. Vanek, PhD – GM Cell and Gene Therapy Strategy and Business Development, GE Healthcare
Phil is General Manager of GE Healthcare’s Cell and Gene Therapy business development and strategy, a business formed to address the unique challenges of cell and gene therapy manufacturing and distribution. Prior to joining GE, Phil was Head of Business Development for Cell Therapy, and later Head of Innovation for Lonza’s life science business.
Phil’s career has included a number of innovation, business and market development roles at Becton Dickinson, Invitrogen, and Life Technologies, as well as two start-up biotechnology companies in the Washington, DC area. Additionally, Phil was an Instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program.
Phil received his Ph.D. in Biochemistry and Molecular Biology from Georgetown University Medical Center and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology and the Hollings Cancer Center in Charleston, South Carolina.
Phil is an active board member of the Alliance for Regenerative Medicine and the ARM Foundation, as well as the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto. Additionally, Phil serves on several advisory boards in both not-for-profit and for-profit organizations and associations. Phil has published a number of industry position pieces and serves on the Editorial Board of Cell and Gene Therapy Insights.
Chief Clinical Officer The Cell and Gene Therapy Catapult
Prior to this Jacqueline worked at the Scottish National Blood Transfusion Service in a number of senior regulatory and quality positions, the responsibility for which included designing the regulatory strategy for the Cellular Therapies developed by the Blood Transfusion Service, acting as Responsible Person for Blood and Qualified Person for medicinal product release. Before that she held a number of post-Doctoral academic posts at the University of Edinburgh studying neuromuscular regeneration. She has considerable experience in the development, translation, clinical trial and approval of cell based medicinal products and therapies.
VP Business Development APAC Miltenyi Biotec
As VP of Business Development APAC at Miltenyi Biotec, Hermann is responsible for Miltenyi’s strategic collaborations with Biotech and Pharma in Cell and Gene Therapy (CGT) in Asia. Joining Miltenyi Biotec in 2009, he was instrumental in building Miltenyi’s cell and gene therapy business as Business Area Manager, including the release of key ancillary materials and the T Cell Transduction Prodigy platform. In 2016 he led Miltenyi’s Australian business as Managing Director. Before joining Miltenyi, Hermann was responsible for the project management for early drug and monoclonal antibody development at MediGene Immunotherapies, Munich. He holds a doctoral degree from the University of Bonn and the Helmholtz Research Center Juelich for studies on bioprocess development of DCs and ACT in solid tumor indications. He continued similar studies at King’s College London (Guy’s Hospital) with Cancer Research UK.
Delara is the Vice President of the Cell Therapy Technologies Business at Terumo BCT, committed to delivering integrated solutions and services across the continuum of care in cell and gene therapy space.
Delara received a Ph.D. in Physiology and Biophysics from the University of Illinois, fellowship in Vascular Tissue Engineering at Northwestern University, and Executive MBA from Kellogg School of Management. With more than 15 years in various cross-functional roles in the biomedical and healthcare field, she brings a unique perspective and a deep understanding of the technical, manufacturing and commercialization elements of the industry with a passion to make a difference in the lives of patients.
Vice President of Technical Applications and Customer Support MaxCyte
James Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc., where he has worked for the past twelve years. Dr. Brady received a Bachelor of Science degree in Biology from the College of William and Mary and a PhD in Genetics from Indiana University. He was a postdoctoral fellow in the National Eye Institute of the National Institutes of Health. After leaving NIH, Dr. Brady worked at MetaMorphix, Inc. as a Senior Scientist and Group Leader in the Company’s Transgenic Livestock program. Prior to joining MaxCyte, Dr, Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders.
Global BioPharma Manager - Cell and Gene Therapy Commercialization Beckman Coulter
Neil Kayal has a long standing interest in the cellular manufacturing process with the overarching intent of democratization of personalized medication. He trained in Bioengineering and functional medical resonance imaging at Temple University with a focus on spinal cord injury in pediatric population. His research was on non-invasively quantifying healthy neuronal tissues as a pre-op to assist neurosurgeries. He later started a post-doctoral fellowship at the University of Michigan, investigating the cognitive-affective, psychosocial, and biological processes associated with the etiology and treatment of pathological aggression in patients with Intermittent Explosive Disorder by designing fMRI and DTI protocols and analysis of clinical data. At Beckman Coulter, Neil Kayal manages the global biopharma business commercializing the life sciences portfolio in the cell and gene therapy marketplace.
Manager of Platform Development Specialists Sartorius Stedim (Shanghai)
SHEN Liang (Leon) is currently working as Manager of Platform Development Specialists in Sartorius Stedim (Shanghai) Trading Co. Ltd with a master degree of biochemistry and molecular biology from Huazhong University of Science and Technology (HUST). His current work focuses on the integration of new technologies and building up processes/platform for mono-clonal antibody, vaccine and regenerative medicines, providing consultancy and solutions to accelerate the lifecycle and implement practical Quality by Design (QbD) approach in biopharmaceuticals. In addition, he has years of experience in GMP compliance consultancy, manufacturing process change management, quality risk management of single use technologies/systems, sterility assurance and process validation. Previously he worked for Merck Chemicals (Shanghai) Co. Ltd and Wuxi Apptec Group.
Wei (William) Cao
Founder, Chairman and CEO
Dr. Wei (William) Cao is the founder, chairman and CEO of Gracell Biotechnologies Co., Ltd. Together with an industry veteran team, Dr. Cao has created Gracell to capture special opportunity of cell therapy for global market. Through external partnership and in-house R&D effort, Gracell has been rapidly progressing with novel CAR-T programs to address the industry’s key issues and also the research and development of stem cell therapies.
Dr. Cao has over 30 years of professional experience in scientific research, products development and startups. He was the co-founder and CEO of a Nasdaq listed cellular therapy company. Prior to his venture, Dr Cao served as Technical Manager for Bayer Diagnostics Asia Pacific region, and China General Manager of Affymetrix, a world leader in genetic analysis industry.
Dr. Cao earned a Bachelor’s degree in Medicine from Fudan University Medical College, China and a PhD degree in Pharmacology from Medical College of Virginia, USA. He has extensive research experience in immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. He is invited as the director of International Chinese Stem Cell Foundation (ICSCF), and served as Venture Partner of 6 Dimensions Capital. Dr. Cao received prestigious White Magnolia Award from Shanghai City.
Dr. Cao is also an inventor of more than 70 patents in the field of stem cell and CAR-T technologies.
Founder and CEO Eureka Therapeutics
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.
Dr. Zhang Yu is the president and CEO of Aeon Therapeutics Inc., a joint-venture biotech company established by Eureka Therapeutics Inc. and Vcanbio Cell&Gene Engineering Co.,Ltd. Prior to found Aeon, Dr. Zhang acted as assistant president and senior strategic planning expert in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Before the industrial career, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan”and “Tianjin Green Card Plan”.
Chairman & CSO
Innovative Cellular Therapeutics
1. Chimeric antigen receptor T cells therapy,
2. iPS cell technology & human embryonic stem cells
3. Gene therapy
● October 2005-September 2010: Shanghai Institute of Biochemistry and Cell Biology. Principal Investigator.
● Jan 2007- September 2010: Cell Bank/Stem Cell Bank of Chinese Academy of Sciences. Shanghai Institute for Biological Sciences. Director.
● October 2010-2015: Zhejiang University, Professor.
● August 2009-Present: Innovative Cellular Therapeutics CO., LTD.(Formerly Shanghai SIDANSAI Biotechnology Co,LTD）, Chief Science officer.
I have long been engaged in the study of human embryonic stem cell research for nearly 20 years and focus on chimeric antigen receptor–modified T cell therapy targeted leukemia and solid tumors in recent years. In 2008, my lab successfully established the first iPSC line in China by a 6-factor scheme which highly enhanced the induction efficiency and speed. In the same year, we established the first rat iPSC line in the world. In 2009, Our group established the first pig iPSC line with a tetracycline inducible system, and this work would provide important criterion for pig ESC. Two years later, the first clone pig in the world were born, proving that pig iPSC could be a source to obtain clone pig, and we can get gene-modified pig through this technique. Inspired by the tremendous potential of chimeric antigen receptor-modified T cell to cancer therapy and the faith to transition the technology from laboratory to the clinic, I started CD19 CAR-T research in 2012, We conducted a multicenter clinical trial to study safety and efficacy of autologous CD19 targeted CAR-T cells after the success in the in vitro experiment and the mice model. Between May.4 2015 and January. 12 2017, a total of 40 cases with relapsed/refractory B-ALL received SDS-19CAR-T cells at doses of 0.45 × 10E6 to 10.51 × 10E6 per kilogram of body weight. 83% (34/41) of the patients achieved complete remission (CR) and 80% (33/41) of the patients achieved MRD negative between Day7-14 after CD19 CART cell infusion.
Tony (Bizuo) Liu
Chief Executive Officer, Chief Financial Officer
Cellular Biomedicine Group
Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider.
Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.
Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.
CEO Fosun Kite Biotechnology
Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D of Molecular Biology from the University of Maryland, Baltimore, and MBA from Xavier University, Cincinnati in the US. He obtained his post-doctoral training at the National Institutes of Health, Baltimore, USA.
Richard now is the CEO of Fosun Kite Biotechnology. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.
Richard is very experienced in biopharmaceutical industry. Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
CEO and Co-Founder JW Therapeutics
Dr. James Li is the CEO and co‐founder of JW Therapeutics; previously he was a partner of KPCB China and General Manager of Amgen China.
Dr. James Li was the founding General Manager for Amgen in China, where he led the
company's efforts in expanding its business into the Chinese market to help Chinese
patients gain access to Amgen's vital medicines.
Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life
science practice, first in the US Pandemic Fund and later, in its China Fund. He
successfully invested in early stage university spin out, growth stage companies and
led a portfolio company went to public in 2010.
From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held
leadership positions with increasing responsibilities in clinical research, regulatory
affairs, new product development and franchise management, both in the US and Asia
Pacific/China. During his tenure, he was instrumental in obtaining regulatory
approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division
started operations in the region, successfully built the foundations of Merck's medical
operations in China and drove the success of Merck's largest franchise in Asia.
James received his Medical Degree from Shanghai Medical University followed by a
Master of Science degree in Microbiology from the University of Montana.
Chief Scientific Officer Tessa Therapeutics Pte Ltd
Dr. Connolly is the CSO of Tessa Therapeutics, a Senior Principal Investigator and Director for Translational Immunology at the Institute of Molecular and Cellular Biology (IMCB). As a human immunologist, his research interests focus on target discovery for immune modulation. An Adjunct Associate Professor of Immunology at Baylor University, he served on the Board of Governors for the Institute of Biomedical Sciences.
Dr. Connolly received his Ph.D. in Immunology from Dartmouth Medical School and studied human dendritic cell biology under Dr. Michael Fanger. During this time, he was involved in the development of immunotherapeutic preclinical models and clinical trials for Glioblastoma multiforme (GBM). He moved to the Baylor Institute for Immunology Research, a fully translational research institute dedicated to rationally designed vaccines against cancer and infectious disease. Dr. Connolly served as the Director of Research Initiatives for the Baylor Research Institute, leading a large integrated translational research resource and multi-institutional programs. During his tenure at Baylor, Dr. Connolly was a central core facility director of the NIAID Centers for Translational Research on Human Immunology and Biodefense, an NIH funded consortium of basic, translational research and clinical trials focused on vaccine design. Dr. Connolly is the past President of the Board of Directors of The American Cancer Society in N. Texas.
Site Head, Head of Medicinal Chemistry, Head of External Innovation, Therapeutic Modalities
Roche Innovation Center Shanghai
Hong Shen is the Site Head, the Head of Medicinal Chemistry, and the Head of External Innovation at Roche Innovation Center Shanghai (RICS). Hong joined RICS in Jan. 2012, and his teams in medicinal chemistry have contributed to programs in antiviral, antibiotics, immunology, inflammation, oncology and other therapeutic areas, which led to the discovery of multiple clinical compounds. Prior to his career at Roche, Hong spent over 9 years at Merck (USA) working on drug discovery in the areas of hypertension, diabetes, thrombosis, atherosclerosis, and obesity.
Hong is an expert in medicinal chemistry with over 90 publications and over 60 patent applications. He is on editorial board of three journals/book series. Hong is a Fellow of the Royal Society of Chemistry (FRSC), and a lecturer at Shanghai Jiaotong University School of Pharmacy, Tsinghua University School of Pharmaceutical Sciences, and CCDRS, Peking University.
Hong received his B.S. from Peking University and Ph.D. in organic chemistry from Stanford University
Chief Executive Officer Jing Medicine
Dr. Michael Xie is the Chief Executive Officer of Jing Medicine. Prior to joining Jing Medicine, Dr. Xie held various senior executive positions at pharmaceutical and biotechcompanies in US and China. From 2014-2016, he was VP and General Manager of Chinaat Zebra Biologics Inc. which is based in Boston, USA. From 2007-2013, he was SeniorDirector of Discovery Technology, Oncology, and iTCM at GlaxoSmithKline (GSK),R&D China in Shanghai. Previously, Dr. Xie worked as Director and Sr. Scientist at several biotech companies in the US including Synta Pharmaceuticals and MillenniumPharmaceuticals in Massachusetts.
Dr. Xie received a B.S. from Medical School of Fudan University and a Ph.D. in Neuro-pharmacology from Northeastern University, Boston, MA. Dr. Xie did his postdoctoraltraining in Neurobiology Department, Harvard Medical School
CEO and co-founder Eccogene
Dr. Zhou is Chief Executive Officer and co-founder of Eccogene, an immune and metabolism focused biopharmaceutical company founded in 2018. Prior to founding Eccogene, Dr. Zhou was the head of chemistry at Lilly China R&D Center, where he led project teams to achieve candidate selection milestones for diabetes and diabetic complications. Before joining Lilly in 2012, Dr. Zhou was investigator at GlaxoSmithKline working on drug discovery campaigns utilizing disruptive DEL technology. Dr. Zhou began his career at Tetraphase pharmaceutical, where he co-invented Eravacycline, an FDA approved drug for cIAI. He holds a Ph.D. in chemistry from Brandeis University and received a B.S. in life science from Fudan University.
Co-founder and CEO GenFleet Therapeutics Inc.
Dr. Jiong Lan is co-founder and CEO of GenFleet Therapeutics. Before founding GenFleet, he was the General Manager of Haiyan Pharmaceuticals, a wholly owned subsidiary of Yangtze River Pharmaceuticals, which focused on novel drug discovery and development. Prior to that, Dr. Lan served as a Sr. Scientist at Hengrui Medicines. Dr. Lan started his industry career at Triad Therapeutics in 2002, and then Neurogen Corp. in 2004. In 2005, He moved to Chiron Corp., later became part of Novartis Institute of BioMedical Research, where he had led multiple projects yielding numerous clinical stage compounds. Dr. Lan finished his postdoctoral training at University of Rochester at Rochester, NY, after receiving his Ph.D. in Organic Chemistry from Lanzhou University in Lanzhou, China. Dr. Lan has more than 80 publications and patents worldwide. He has developed numerous compounds which being moved into various clinical stages, spanning multiple disease areas.
Vice President, Head of Chemistry Haiyan Pharma of Yangzi River Pharmaceuticals
Huiping Amy Guan is the VP and Head of the chemistry department at Haiyan Pharma. She brings over 20 years of broad experience in the pharmaceutical industry and CRO, advancing therapeutic candidates through discovery to FTIM. From 2012 to 2017, Amy was the collaboration head at WuXi Apptech IDSU for multiple client companies. She led integrated service teams to design, synthesize and evaluate compounds as potential drug candidates. She delivered several PCCs and 3 of them are currently in clinical trials. From 2004 to 2011, Amy was a team leader and medicinal chemistry designer at AstraZeneca Boston, where she led and contributed to many cancer projects. Between 2000 and 2003, Amy delivered clinical drug SU14813 and became a project chemistry leader at Sugen. Inc. of Pfizer in San Francisco. Amy obtained her PhD degree in Synthetic Chemistry at Shanghai Institute of Organic Chemistry, Chinese Academy of Science, and did her Post Doc. research at Michigan Cancer Foundation, USA.
Vice President, Head of Chemistry Jing Medicine
Dr. Hui Lei is currently VP, head of chemistry at Jing Medicine. Jing Medicine is an innovative pharmaceuticals enterprise focusing on early drug discovery and development. Prior to joining Jing Medicine, she was associate director at Lilly China Research and Development Center and GSK R&D China. She also held various positions at ChemPartner and CoMentis Inc. During her 15+ years of career in pharmaceutical industry, Dr. Lei has been the leader of various projects including protease inhibitors, nuclear receptors, kinase inhibitors, and GPCR. These work led to multiple clinical candidates targeting neuroinflammation diseases, Alzheimer’s Disease and Metabolic diseases. She is an inventor of multiple issued patents. Dr. Lei received a B.S. in chemistry at Peking University and a Ph.D. in organic chemistry at University of Illinois at Chicago.
Founder and CEO Insilico Medicine, Inc
Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013).
He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging
CSO FOSUN Pharma
Hequn Yin is currently CSO of Fosun Pharma. Prior to joining Fosun, Hequn was a VP of Pfizer Oncology R&D in California, USA. Before Pfizer, he spent nearly 20 years with Novartis in New Jersey, USA where he held positions of increasing responsibility from a Sr scientist to an Executive Director. Hequn also worked at Hoffmann-La Roche in New Jersey during 1997-98.
Hequn received a B.S. in chemistry from Peking (Beijing) University in 1985 and a M.S. from the Chinese Academy of Sciences in 1988. He earned a PhD degree in pharmacology from the University of Rochester, USA in 1995. Subsequently he conducted post-doctoral research in molecular biology & biochemistry at UC San Francisco, USA between 1995 and 1997. He also attend the eMBA program at Fairleigh Dickinson University in New Jersey.
Professor & Executive Director Institute of Molecular and Cell Biology (IMCB), A*STAR ( upon final confirmation )
Prof Wanjin HONG graduated from Xiamen University in 1982 and was one of a few hundred Chinese students chosen for further graduate training in the United States via the CUSBEA (China–United States Biochemistry Examination and Application) program. He received his PhD from the State University of New York (SUNY Buffalo), and was a postdoctoral fellow there before he joined the Institute of Molecular and Cell Biology (IMCB) in Singapore as a PI in 1989. He became the Executive Director of IMCB at A*STAR (Agency for Science, Technology and Research) in 2011. He was the recipient of Singapore’s National Science Award (now President’s Science Award) in 1999. He also received Singapore’s government Public Administration Medal (Silver) in 2014. He serves as the Editor-in-Chief of Bioscience Reports, Associate Editor of Cell & Bioscience, and is on the editorial board of TRAFFIC.
Co-Founder, Chairman & CEO BeyondSpring Pharmaceuticals
Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.
Prior to founding BeyondSpring in 2013, Dr. Huang co- founded Wuxi MTLH Biotechnology Co. Ltd., whose self-designed cancer peptide drug’s China rights were acquired by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China, in 2010. She also co-founded Paramax International, a Clinical CRO company in China, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In addition, Dr. Huang worked with Forward Ventures where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies. Dr. Huang was trained at Memorial Sloan-Kettering Cancer Center and received her Ph.D. in Chemistry from University of California at Berkeley, where she won the graduating Ph.D. woman award. Her translational research in cancer signaling pathways involving Ras and P53 were published in Science and Nature. Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she currently serves as a Trustee. She also studied at Fudan University in Shanghai, China.
President, Chief Medical Officer and Board Director Adlai Nortye Biopharma
Dr. RuiRong Yuan is the President, Chief Medical Officer and Board Director of Adlai Nortye Biopharma. She previously served as Chief Medical Officer & President of global clinical development at BeiGene; Chief Medical Officer and Vice President of Eisai Global Oncology, Head of multiple therapeutic areas at Daiichi Sankyo and senior global clinical leader at Novartis Oncology. Dr. Yuan has decades of successful drug development experience and played a critical leadership role in the development, regulatory approval and commercialization of multiple compounds, including anti-cancer drug Afinitor, Zelboraf, Lenvatinib, Halaven and anti-PD-1 combination regimens. She has been a frequently invited speaker at national and international oncology meetings and has established strong collaborations with internationally recognized key opinion leaders to promote new drug development in oncology.
Dr. Yuan is an US-board certified medical oncologist and attending physician at VA Medical Center of New Jersey Medical School. She has had extensive academic clinical practice and research experience as a physician-scientist at top cancer centers in China, Switzerland and the US. She has published many peer-reviewed original research articles and holds multiple patents related to either cancer treatment or autoimmune disease therapy.
Dr. Yuan also remains actively involved in promoting cancer research collaborations between the hematology and oncology communities in the west and east worlds. She is one of the founding members of Chinese American Hematologist and Oncologist Network (CAHON) and served previously as its president and Board chair. She has been an executive member of the Chinese Society of Clinical Oncology (CSCO) since 2004 and served on the ASCO-International Affairs committee from July 2006 to June 2009. She also serves as editor for multiple Journals of hematology and Oncology. Dr. Yuan is the guest professor at Shandong University hospital and HeNan University Hospital, and she serves the vice chair of CSCO-COE (committee of overseas experts), a new organization to further strengthen the global cancer research collaboration and improve cancer care through education, research and clinical service.
Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development BeiGene
Dr. Lai Wang is our SVP and head of China development. Dr. Wang received his B.S from Fudan University in 1996 and Ph.D. from University of Texas Health Science Center at San Antonia in 2001. Dr. Wang joined BeiGene from the early days of the company in 2011, his role has changed over the years within the organization. He was initially leading the Discovery Biomarker and In Vivo pharmacology groups. Starting from 2013, Dr. Wang supported the clinical programs in the role of Clinical Biomarkers and Translational Research. In 2016, Dr. Wang was pointed as the Head of China Development, responsible for the clinical development in Asian-pacific region. Prior to joining BeiGene, he was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas. and had post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute. Dr. Wang has 10 years experience in biotech industry on both research and development, and over 20 years in cancer research and oncology field.
Chief Medical Officer, Oncology Zai Lab
Dr. Hei is the CMO at Zai Lab where he oversees the clinical development and portfolio strategy for all the oncology projects. Prior to Zai Lab, Dr. Hei was the Corporate VP and CMO at Qilu Pharmaceuticals where he led the overall clinical development functions and supported business development and strategic alliances. Previously, Dr. Hei worked at the San Diego-based biotechnology company Ambrx Inc. for more than 2 years as the CMO responsible for the clinical strategy and operations, focusing on antibody-drug conjugates (ADCs) and CD3-based biospecifics. Prior to Ambrx, Dr. Hei had worked at Amgen for more than 9 years before joining Ambrx, initially as the Head of Oncology Medical Affairs, and subsequently as an Executive Medical Director in Oncology Global Development in the capacity of a group or project leader for several oncology pipeline molecules and marketed products including the small molecules VEGF inhibitor motesanib and monoclonal antibodies targeting the death receptor DR4/5 (conatumumab) or the EGFR (panitumumab or Vectibix®). Additionally, during his tenure at Amgen, Dr. Hei built the clinical medical teams for Amgen China in Shanghai and led the product development and clinical operations function for Amgen China. Before Amgen, Dr. Hei worked for a few years at Novartis oncology as the Senior Global Brand Medical Director/Executive Director leading the clinical development and medical affairs teams for zoledronic acid (Zometa®), and for a few years at Roche Laboratories as the oncology Medical Director supporting capecitabine (Xeloda®) and other oncology projects.
Chief Medical Officer
Dr. Jason Yang serves as the Chief Medical Officer for CStone Pharmaceuticals, who had over 25 years of biomedical research and new drug R&D experience in US and China, from discovery, translational medicine to clinical development.
Prior to joining Cstone, Dr. Jason Yang served as the Senior Vice President and Head of Clinical Development at BeiGene since 2014. He and his team generated key safety and proof of concept efficacy data that supported BeiGene’s two successful financing rounds in 2014 and 2015 and the IPO and a follow-on offering in the US NASDAQ market in 2016. Prior to joining BeiGene , Dr. Yang served as Oncology Medical Director at Covance, Senior Principal Scientist in oncology translational biomarkers at Pfizer and Research Scientist in cancer genomics at Tularik/Amgen.
Throughout his career, Dr. Yang has made significant contributions to the successful development of several anticancer drugs. He is also the author of over 30 publications and the inventor of 9 patents. In 2015, he is honored as a “Distinguished Expert” by the China’s national “1000 Talents Program” and the Beijing “Haiju Program.”
Dr. Yang was trained as a physician at Hubei Medical College and Nanjing Medical University. He then received his PhD training with Nobel Laureates Drs. Mike Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center at Dallas. He completed his postdoctoral training with Dr. Stuart Schreiber at Harvard University.
Xiang Yang Zhu
CEO Huaota Biopharm and Huabo Biopharm
Dr. Zhuis an expertin antibody drug discovery and process developmentwith more than 18 yearsof industrial experience. Hehas extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research.Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations (Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led andengaged inover 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhDin microbiology and immunology fromtheUniversity of Illinois at Chicagoand has authored more than 20 publications in peer-reviewed journals.
Dr. Guo is the VP of CMC at Asieris Pharmaceuticals where he oversees the pharmaceutical and analytical development, and outsourcing management of both drug substance and drug product. He received his Ph.D. from Iowa State University and completed his postdoctoral training at the Pharmacy School of University of Wisconsin-Madison. Dr. Guo has over20 years of experience in pharmaceutical R&D and management. He previously worked at Merial, Aventis, Sanofi, Achaogen, and WuXi AppTec/STA. His expertise includes NCE developability assessment, drug analytical and stability, solid-state chemistry, preformulation, preclinical and clinical formulation development, GMP, and CMC management. He served as organizing committee member of AAPS/PhRMA International Conference on Drug Stability and is the reviewer for several international pharmaceutical journals.
Weiyi Zhang is currently the director, external innovation China and head of Research Beyond Borders China at Boehringer Ingelheim. She is responsible for setting up collaborations in China for research functions at BI. Weiyi gained her bachelor degree in Biology at Xiamen University in 2001. She joined international Max-Planck research school in chemical biology in 2003 and studied function of olfactory G-protein coupled receptor in non-olfactory tissues. She obtained her Ph.D in cell biology from Ruhr-University Bochum in 2007. Since 2008, Weiyi started postdoc training in functional study of orphan GPCRs in central neural system at both National Institute of Biological Sciences and the University of Hong Kong.
Before joining Boehringer Ingelheim, Weiyi has led a cell biology group at BioDuro-PPD in Beijing since 2009, focusing on cell-based assays and integrated early drug discovery programs for various pharmaceutical companies. Then she has led the monoclonal antibody research group at Bio-Rad Laboratory in Shanghai from 2012 to 2013. From 2013 to 2016, Weiyi was the associate director of Innovation Partnering at Innovation Center China of Global Drug Discovery at Bayer Healthcare.
SVP, Cardiovascular and Metabolic Disease Research
Dr. Wang graduated from Fudan Medical college, started his career as a postdoctoral researcher in Boston University, later as an assistant professor in University of Tennessee at Memphis. He has since worked in several major pharmas (GSK, Roche, Schering/Bayer AG) and a startup biotech (Arete), and joint CrownBio as an SVP, Cardiovascular and Metabolic Disease Research. He has been working in cardiovascular and metabolic research area with ~100 publications in research articles, invited reviewers, book chapters, and patent applications.
Annastasiah Mudiwa Mhaka
Co-Founder and President Alliance for AI in Healthcare (AAIH)
Sr. Advisor Adjuvant Partners
Dr. Mhaka is an experienced life sciences executive, investment professional, and biotech entrepreneur with a passion for global health. Leveraging expertise in biomedical discovery, technology development, healthcare delivery, and fundraising she creates transformative healthcare advances impactful on a global scale. Utilizing her experience in cross-disciplinary and multi-stakeholder approaches, Dr. Mhaka has co-founded the Alliance for Artificial Intelligence in (AAIH) , a global organization dedicated to resolving the myriad challenges facing the growing field of AI and Machine Learning based life sciences and healthcare solutions. In addition to her proven track record of over 50 cross-industry deals in both the private and public sector, Dr. Mhaka has co-founded four companies, and generated over $200 million in deliverables within the drug development and nanotechnology sectors. Dr. Mhaka received her PhD in Cellular and Molecular Medicine from Johns Hopkins Medicine where she developed a clinical phase oncology drug and attained her Bachelor of Science in Chemistry [Highest Honors, Summa Cum Laude] from the University of Pittsburgh.
Executive Director, Head of Data Science in China
Dr. Guo currently is an Executive Director, head of data science in China for BeiGene, a Nasdaq listed Chinese biotech company. Before joining BeiGene, Dr. Guo served as Senior Director, head of AP Statistics group of Merck Research Laboratories, from 2013 to 2017. As a core member of MSD’s China development committee, Dr Guo made significant contributions to the development and approval of Keytruda, Gardasil and Zepatier in China. Dr. Guo also worked in Sanofi China and Sanofi USA as the manager of statistics group and the lead statistician for Sanofi’s best seller Lantus in Sanofi US.
Dr. Guo received his Ph.D. degree in Statistics from North Carolina State University. His research interests focus on statistical inference in Multi-regional Clinical Trial, benefit risk assessment, missing data analysis and adaptive design. Besides his industrial position, Dr. Guo also holds adjunct teaching positions in Beijing Normal University. Dr. Guo is the chair of DIA China statistical community, a member of DIA Advisory Committee of China, a member of China Clinical Trial Statistics Working Group (CCTS) and the secretary general of Beijing Biometrics Association.
Director, Health Informatics
Xia holds a director and senior leader position at Health Informatics team within advanced analytics center at AstraZeneca global medicines development unit. Xia has records of accomplishment in applying novel data driven solutions and real world data analytics to all phases of medicines development life cycles from early drug discovery to late phase clinical development and commercialization. Xia has 18 years of experience in pharmaceutical industry with scientific focus spanning neuroscience, infection, diabetes, respiratory and autoimmune therapeutic areas. Currently Xia is leading informatics efforts in AstraZeneca Real World Evidence (RWE) to support clinical and observational studies, medicines comparative effectiveness, payer & pricing strategy and marketing accessing research. Prior to stepping into the clinical domain, Xia was with the AstraZeneca drug discovery in the areas of informatics and computational modeling to support candidate drug identification and optimization. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.
Director, Biomarker and Exploratory Analysis
Dr. Jie Cheng is a director at Abbvie Inc., leading biomarker and exploratory analysis. Dr. Cheng received his PhD in Computer Science in 1998 and completed his postdoctoral training in AI & Machine Learning in 2000. He has more than 15 years of experience in applying machine learning and predictive modeling to clinical and biomarker data analysis. He has won several data mining competitions including ACM KDD-cup and FDA led MicroArray Quality Control data analysis.
Mr. Alex Liu received his M.S. degree in molecular pharmacology from Peking Union Medical Collage and an LLM degree in IP Law from Franklin Pierce Law School (US). Mr. Liu is qualified both as a patent attorney in China and a patent agent in the US. As an experienced patent practitioner working in a multi-national company in China, Mr. Liu is adept at developing IP strategies and managing IP portfolios that position businesses to take advantage of both legal and business opportunities.
As part of his previous practice as an external counsel, Mr. Liu provided expert advice on issues including patentability, validity, infringement, freedom-to-operate, due diligence, etc. After joining Bayer China since 2007, Mr. Liu also helped his company draft and negotiate technology transfer agreements, IP licensing agreements, and other contracts related to IP transaction in the areas of pharmaceuticals, agrichemicals, biotechnology, and medical devices. As now being the IP Head of Bayer China since 2013, he is conducting/coordinating all types of IP issues for the company in the APEC region.
Director, Search & Evaluation, JAPAC AbbVie China
Dr. Bin Li is currently Director, Search & Evaluation, JAPAC at AbbVie in Shanghai, responsible for search and evaluation of partnership opportunities in key therapeutic areas of immunology, oncology, neuroscience, and liver diseases. Prior to joining global S&E team in July 2015, he was site head of AbbVie China R&D Center in Shanghai which focuses on pre-clinical drug discovery in several therapeutic disease areas including chronic kidney diseases. Dr. Li joined Abbott R&D Center, Shanghai in September of 2008 to head the center and carry out drug discovery research in several key therapeutic areas, and continued to head the center following separation of pharmaceutical business and formation of AbbVie. Prior to Abbott, Dr. Li was Vice President, Service Biology at ChemPartner to build and lead the service biology division. Before returning to Shanghai, he spent 16 years in US pharmaceutical and biotech companies, including Roche, Pfizer, Anadys, and Xceptor, with various titles from Research Scientist to Director to lead and support drug discovery research as well as drug screening and lead discovery technologies such as ATLAS, an affinity-based high throughput screening platform for protein ligand identification. Dr. Li received his B.S. from Lanzhou University in China in 1982, M.S. from Iowa State University in 1986, and Ph.D. from Penn State University in 1990. Dr. Li has more than 25 years of drug discovery experience in various therapeutic disease areas.
Professor, Bioinformatics Department
Dr. Qi Liu is now the full professor in the Bioinformatics Department in Tongji University, China and lead the BM2 group (Biological and Medical Big data Mining group) for bioinformatics and translational medicine study. Dr. Qi Liu has published 60+ high quality papers in the leading journals including Genome Biology、Nature Communications、Trends in Biotechnology、Trends in Pharmacological Science、WIREs Computational Molecular Science、Clinical Pharmacology & Therapeutics、Bioinformatics et c and developed a bunch of tools for drug discovery and high throughput sequencing data analysis. Dr. Qi Liu has won the 7th Wuwen Jun AI award in China for his contributions to apply AI for drug discovery and Precision Medicine.
Professor and Principle Investigator
National Institute of Biological Sciences (NIBS)
Dr. Niu Huang is a principle investigator at National Institute of Biological Sciences (NIBS), Beijing. He has authored and coauthored over 50 peer-reviewed publications in leading journals in the fields of computational chemistry and medicinal chemistry, and has applied 10 international drug patents. Dr. Niu Huang is interested in developing and applying computational chemistry approaches to predict the binding free energy of protein-ligand interactions. Aside from its fundamental scientific interest, such physics-based approaches have tremendous practical values in structure-based drug design. His lab has demonstrated that the incorporation of more accurate treatments of physical interactions greatly facilitates structure-based ligand discovery. Currently, his lab has pursuing preclinical development of several novel drug candidates in treating unmet medical needs, and these compounds have served as specific chemical probes to facilitate the in vivo functional studies of the protein targets of interest.
GigaCeuticals Co., ltd
Dr. Xie obtained PhD degree at Center of Quantitative Biology in Peking University, jointly trained in UCSF. He started to get an interdisciplinary education from Nanjing University. He developed the microfluidic chip that facilitating yeast aging studies and featured by Nature. His study on Early Telomerase Inactivation (ETI) resulted in a potential solution in treating pre-mature aging, published at Cell. In computational biology, he developed Hyper Cube Shrink Algorithm (HCSA) to evaluate the causal relationship of enzymes and flux (Bioinformatics 2018).
Dr. Xie now is Principal Investigator of his lab at Department of Pharmacology, in Peking University. He is a committee member of Chinese Pharmacological Society Pharmacoepigenetic Committee. He won Huangtingfang Reward in 2018. The lab focused on drug development for aging, aging related diseases and metabolic diseases. He founded GigaCeuticals, which developed a computational platform, named DeeperPharma, based on various neural networks. DeeperPharma is a method combining all steps of evaluation from chemical formula to animal test. It achieved higher standard small molecules and testable accuracy. GigaCeuticals obtained angel fund from INNOANGEL and POWERCLOUD.
President & CEO, Adjunct Professor
Dr. Sun, CEO & President of AbMax Biotechnology, Inc., Adjunct Prof. of Beijing Normal University. Dr. Sun has more than 30 yrs experience in antibody-based cell signaling research and drug development. Dr. Sun received his PhD in biochemistry/cell biology from Tsinghua University (Beijing) in 1989, working on EGF cell signaling. Dr. Sun was a postdoctoral fellow in Dr. David Barnes’s lab at Oregon State University, working on embryonic stem cells. Dr. Sun was Director of R& D at Upstate Biotechnology Inc., a market leader in the biotechnology research reagent sector for cancer biology. His team introduced 200+ new antibodies and enzymes every year. In 2000, as a co-founder and the President, Dr. Sun started A&G Pharmaceutical in Baltimore, created the record of “Generation of mAb in 28 days” for MedImmune and received $2.5 M investment from MedImmune in 2001. In 2004, Dr. Sun returned to Beijing, China, and started Welson Pharmaceuticals working on antibody drug conjugate (ADC), now has one leading candidate in co-development with a Chinese Pharma. In 2006, Dr. Sun started AbMax as a Biotech CRO. Using AbEpiMax, the ONLY B cell-epitope identification program, his team has generated >10,000 antibodies against over 5000 different targets, many of which have been published in well-known journals such as Nature Medicine. His team also has extensive experiences in establishments of assays for immunogenicity and PK study of antibody drugs and other biologicals. Dr. Sun has published 40+ papers on journals such as Nature Med., Nature Genetics, Immunity, Development Cell, etc. He holds 8 issued patents and filed many.
Executive Director, Asia Pacific Innovation Hub
Min has 15 years of pharmaceutical and biotech R&D and business development experience.
Min is currently Executive Director of the Asia Pacific Innovation Hub of MSD, responsible for R&D business development (in-licensing/M&A) in various therapeutic areas (Oncology, Immunology, Inflammation, Metabolic Disorders, Cardiovascular Diseases, Infectious Diseases and CNS) and enabling technology covering the Greater China area. Before MSD, she was the Head of External R&D and Licensing for Amgen Asia R&D Center, responsible for the center’s scientific outreach and alliance management of the external strategic partnerships. She was also in charge of Search & Evaluation for Amgen’s Global Business Development for the JPAC region. Min worked in different functions at Roche including Partnering, Alliance and Portfolio Management.
Min obtained her Ph.D. in computational biology and chemistry from New York University, conducted post-doctoral research at Pfizer La Jolla site and subsequently worked as principle scientist at GlaxoSmithKline in North Carolina. Min has an MBA from University of Manchester, UK.
Zhejiang Jiuzhou Pharmaceutical
Dr. Zhenrong Guo is the Vice President of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. and CTO of Zhejiang Raybow Pharmaceutical Co. Ltd. He previously served as CEO of CDMO Division, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.; Vice President of Apeloa Pharmaceutical Co. and Executive Vice President of Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.; and Vice President at Sundia MediTech Company, Ltd. He was a senior researcher investigator and research project manager at Bristol-Myers Squibb.
Dr. Guo has engaged in pharmaceutical R&D, API manufacturing, quality, and regulatory filing for 30 years including Phase I to III for new drug development and NDA for new drug launch. Dr. Guo has published 26 papers and filed 29 patents in US and China. His research interests focus on anti-tumor, diabetes and Alzheimer's disease. While at Bristol-Myers Squibb, Dr. Guo made significant contributions for 2 new drugs launched in US and worldwide in 2007 and 2012, respectively. Dr. Guo has extensive experience in FDA, EU, WHO, and CFDA regulatory affairs and hand-on experience on handling FDA, EU, WHO, Japan PMDA, and Chinese FDA authorities on-site inspections.
Dr. Guo received his Ph.D. from The University of Western Ontario, MBA from Fairleigh Dickinson University, and postdoctoral fellows from University of California at Berkeley and Monell Chemical Senses Center.
Chief Technology Officer
Dr. Shijie Zhang, currently serving as Chief Technology Officer at PharmaBlock, is leading initiative to extend the team’s competence in process development and manufacturing to support clients’ late phase and commercial programs. Dr. Shijie Zhang has 20 years of combined experience in medicinal chemistry, process chemistry, and API manufacturing. Before joining PharmaBlock, he led the CMC API team at Agios for the two FDA-approved therapies (Idhifa®, Tibsovo®), by managing and overseeing API development programs and manufacturing activities spanning from preclinical stage to commercial stage, and preparing API sections of regulatory filing documents, including IND, IMPD, NDA, and briefing documents.
Green, Griffith & Borg-Breen LLP
Chris is a seasoned IP trial lawyer with over 30 years of experience exclusively in pharmaceuticals, chemicals, medical devices and biotechnology. He has been lead counsel in trials and appeals in the US
District Courts and the Federal Circuit, and is a former adjunct professor of patent law.
As an IP expert, he provides strategic formulation, portfolio development and pre-litigation counseling concerning IP and related FDA issues affecting 505(b)(1), 505(b)(2) and ANDAs (Hatch-Waxman) as well as biologic products (BPCIA), including PIV certifications, Orange Book issues, and related FDA issues.
Due diligence, opinions (validity, freedom-to-operate) whether involving API/excipient selection, trade dress, trademark, formulation attributes, or labeling, and patent preparation/prosecution, are also part of his practice.
He has been recognized as a “Global IP Star” by LMG Life Sciences, a “Life Sciences Star” by Managing IP, an “IAM Patent 1000” litigation attorney, and an Illinois “Super Lawyer,” among other honors. His full bio may be viewed at: https://www.greengriffith.com/team/detail/christopher-t-griffith
Head Patents China
Novartis Pharmaceuticals ( China )
Head Patents China, Novartis Pharmaceuticals (China)
Kent Yang joined Novartis Pharma China as a Patent Attorney in 2012. He is now heading the China Patent Team, providing patent and other IP supports to all local business units and franchises of Novartis Pharma and Novartis Oncology in China. His team’s responsibilities range from patent matters such as patent prosecution, invalidation, infringement, and due diligences, to other IP areas such as technical trade secret disputes, regulatory data protection, name creation and trademarks, copyright, and etc.
Before joining Novartis, Kent was a patent attorney with the Shanghai-based patent firm Shanghai Patent and Trademark Law Office for 7 years.
Kent is a qualified patent agent in China, and holds a bachelor degree in Biology and a master degree in Tumor Pharmacology
Chief IP Officer
3S Pharmaceutical Group
Li Caihui is Patent Attorney\ Senior Engineer\Licensed Pharmacist
√ Sept. 1988-July 1992, Bachelor, Department of Pharmacy, Shenyang College of Pharmacy
√ Aug.-Oct. 1993, Synthesis of peptides Beijing Medical University
√ Feb. 2002, Training on IPRs AOTS training center( Tokyo Japan)
√ 30 cases of patent invalidation /administrative petition with MNC on antibody medicine in China
√ Invalidation on ZL20061008639.X is honored as one of 10 national cases on patents reexamination and invalidation in 2014
√ 2016 Shanghai Labor Medal
Senior Partner, Patent Attorney, Trademark Attorney
Shanghai Beshining Law Office
Mr. Wang is taking charge of Domestic Patent Department and Trademark Department in Shanghai Beshining Law Office. Over 11 years of practice, he has handled hundreds of patent applications. He also successfully handled and won series of patent disputes in the field of chemical and pharmaceutical enterprises , including patent invalidation case referring to Fortune 500 chemical and pharmaceutical enterprises and patent administrative procedure retrial before the supreme court. In 2012, Mr. Wang participated in a training course of US patent law organized by Oliff & Berridge PLC, a famous intellectual property firm in US. Mr. Wang offers intellectual property services to many large chemical and pharmaceutical enterprises and research institutions. He has counseled hundreds of clients, including many well-known domestic and foreign large and medium New Drug R&D companies, Generic Drug Manufacture Companies, Pharmaceutical R&D process companies, R&D institutes such as Henkel KGaA, China National Pharmaceutical Group Corporation (Sinopharm), Shanghai Pharmaceuticals Holding Co.,Ltd, Shanghai Institute of Organic Chemistry under Chinese Academy of Sciences, Shanghai Institute of Pharmaceutical Industry, WuXi AppTec（Shanghai）Co, Ltd, Shanghai Chem Partner Co., Ltd, Shanghai Hisun Pharmaceutical Co. Ltd, Humanwell Healthcare (Group) Co.,Ltd, Yongning Pharma Co., Ltd, Fujian South Pharmaceutical Co., Ltd, Shanghai Morden Pharmaceutical Co. Ltd, Shanghai Zhongxi Pharmaceutical (Group) Co., Ltd, Shanghai Allist Pharmaceutical Co., Ltd, Lianhe Chemical Technology Co.,Ltd, AB Pharma Ltd, Viwit Pharmaceuticals Limited, Hisun Pfizer Pharmaceuticals Co., Ltd ,Arromax Pharmaceutical Technology (Suzhou) Co., Ltd, QR Pharmaceuticals Co., Ltd, Wuhan Kangpu Biological Medicine Co., Ltd, etc.
Dr. Daniel Song is Deputy General Manager of Hrain Biotech. Dr. Song led Hrain team and obtained three (3) INDs out of a total of seven (7) CAR-T INDs approved by NMPA in 2018. He is currently leading collaborations with global organizations in running CAR-T clinical trials in US, EU, and Middle East. Before joining Hrain, Dr. Song had worked at Pfizer and J&J for more than 20 years and his professional career had covered a full span of pharmaceutical development including drug substance and drug product development, manufacturing, quality operations, patent infringement, and drug global registration. He was a Director of Global Regulatory Affairs at Janssen of J&J before he joined Hrain in 2018. He was also a member of Janssen Asia Pacific Manufacturing Leadership Team and helped assess the regulatory impacts from various quality and compliance challenges. Dr. Song established Pfizer Excipient Chemistry Network and was the first chair of the network. He was also a team leader in charge of patent infringement investigations of generic copies of Pfizer name brands on the global market. Dr. Song was a chair of RDPAC CMC Council and was actively involved in discussions with NMPA to improve the regulatory landscape of the pharmaceutical industry of China.
Shanghai HYRZ Biotech Co., Ltd
Co-Founder and Chief Scientific Officer HRYZ （恒瑞源正）Biotech Co. Dr. Joe ZHOU is the co-founder and CSO of HRYZ （恒瑞源正），as well as SYZ （源正细胞）Celltherapy Co. Prior to founding HRYZ，Dr. ZHOU was co-founder of Pegbio （派格生物）Biotech Co. and co-founder as well as chairman of the Board of Shenzhen Yuanxing （源兴基因）Biotech Co. Before that， He was professor of Molecular Pharmacology School of Pharmacy Shanghai Jiaotong University. He published dozens papers in peer reviewed journals including Science，as well as invented mutiple issued Patents. Dr. ZHOU received his post-doc training from Stanford University， Ph. D and MS from University of Hawaii， and BS from Zhongshang University （中山大学）in Guangzhou China.
Chief Executive Officer, Chief Scientific Officer
Founder, CEO and CSO of CARsgen Therapeutics, a leading company on the development of CAR-T cell therapeutics. Dr. Li is a professor in Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li got his M.D. and Ph.D. from Hunan Medical University and Fudan University respectively. Dr. Li is dedicated to developing innovative immune therapeutics to fight cancer. He has advanced several first-in-class CAR-T cell therapeutics for the treatment of patients with pancreatic, gastric, liver cancer and other cancer types.
Chief Executive Officer
UniCAR-Therapy Bio-Medicine Technology
Yu Lei, M.D. / Ph.D., is currently a “Zijiang” Distinguish Professor, Director of the Institute of the Biomedical Engineering and Technology (iBET), East China Normal University, China. He is also a member of Shanghai Pharmaceutical Committee, and member of China Clinical-Research Society of Cell Therapy Specialized Committee; At same time, Dr. Yu was also appointed an Adjunct Professor, Department of Chemical Pharmaceutical and Pharmaceutical and Department of Biological Engineering, University of Utah, US. Dr. Yu is an interdisciplinary experiences in medicine, clinical practice, basic medical research, translational medicine, pharmaceutical research, as well as a successful entrepreneur.
Chief Executive Officer
PersonGen BioTherapeutics, Anke Cellular Therapeutics
Dr. Lin Yang is currently a Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and an adjunct professor of Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. Dr. Yang is the founder/chairman/chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., and Chairman/CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Dr. Yang received many awards, including Innovation and Entrepreneurship Talent of Jiangsu Province, Six Peak Talent of Jiangsu Province, Gusu Innovation and Entrepreneur Leading Talent, Pioneer of Suzhou Industrial Park Technology, Nanjing “321” Technology Leaders, Second Prize of China Innovation and Entrepreneurship Competition, and many other honorary titles and awards. He has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science, etc., which were all funded by international, national and provincial foundations.
As a principle investigator, Dr. Yang plays a major role in the immunotherapy of CAR-T cells and CAR-NK cells of China, and has obtained impressive achievements in the industrialization and clinical trials of CAR-T cell therapy. Among them, several clinical trials are the first projects performed globally, including CD7-CAR-T cell therapy for T-cell acute lymphoblastic leukemia, and 4th generation MUC1-CAR-T cell therapy for solid tumors. Led by Dr. Yang, PersonGen-Anke’s CD19-CAR-T product has been submitted to Chinese FDA and is being under the evaluation process which is expected an approval from CFDA within next few months.
Director, Chief Physician, Distinguished Professor of Changjiang Scholar
Xinqiao Hospital, Army Medical University
Hematologic Diseases Center of PLA Xinqiao Hospital of AMU
Chongqing City Medical Key Discipline and Specialties
Chongqing Hematopoietic Stem Cell Transplantation Center of the CDMP
Chongqing City Medical Quality Control Center of Hematology
The standing committee member of hematology branch of Chinese Medical Association
The chairman of hematology branch of Chongqing Medical Association
The standing committee member of hematology branch of Chinese Medical Doctor Association
The standing committee member of hematological malignancies branch Of Chinese Anti-Cancer Association
Chief medical expert of Chongqing
Editor & Reviewing experts of 《JHO》、《Leukemia research》、《Stem cells》etc.
He presided over 26 national, provincial and ministerial subjects;He published 52 papers of SCI,the highest impact factor is 24.008, and he is the chief editor of 1 monograph and deputy editor of 2 monographs. He won the silver award in the training of the army. He won the first prize of Chinese Medical Science Prize once. He won the first prize of Chongqing Scientific and Technological Progress once and the second prize of it twice. He won the second prize of military medical achievement and military technological progress three times. He won the third prize of China anti-cancer association awards once. He obtained the national patent invention 12 times.
Chief Executive Officer
ImmunoChina Pharmaceuticals Co. Ltd
Dr. Ting He is the founder and CEO of Immunochina Pharmaceuticals. Dr. He received his B.S. in biology from Xiamen University and Ph.D. in cancer biology from Tsinghua University. With years of experience in basic research of cancer immunology, he is dedicated to develop innovative CAR-T therapy for treatment of cancer. He was awarded Beijing Nova program and Beijing Eagle Talents.
Director, Project Management
Werum IT Solutions
Chief Scientific Officer
The Pregene Biopharma Company
As the Chief Scientific Officer in Shenzhen PREGENE Biopharma Company, Ltd, Dr. Zhang Jishuai graduated from Zhengzhou University, receiving a B.S. degree in clinical medicine. Then, he got his M.S. degree in molecular immunology in the Fourth Military Medical University, and Ph.D. in genetics in Beijing Institute of Biotechnology. After that, he obtained the postdoctoral training in the Hormel Institute in the University of Minnesota.
As an expert on tumor biology, Dr. Zhang once did detailed study on tumor gene function (including tumor initiation, differentiation and metastasis), about which he published over 20 papers. In 2016, he founded the PREGENE Company and acted as the Chief Scientific Officer, from which he began the research and development of CART drug. Having built a platform of “Nanobody discovery, CART research and drug development”, PREGENE is now mainly focused on CART therapy for hematologic tumors.
Vice President and co-Founder
Help Stem Cell Innovation Ltd
Kai Zhu, Ph.D. is Vice President and co-Founder of Help Stem Cell Innovation Ltd. He graduated from Institut Pasteur of Shanghai, Chinese Academy of Sciences and authored several papers in peer reviewed journals. When he worked in STEMCELL Technologies, he gained wider experience by close collaboration with prestigious academia and industry. In 2017 he joined Help Stem Cell Innovations Ltd., Co., which provides human iPSC-derived somatic cells and iPSC-based contract services to facilitate drug discovery and development, and is working on developing transplantable organ grafts for stem cell-based regenerative therapies with superior safety and efficacy.
Dr. Jijun Yuan is co-founder and chief executive officer of Shanghai Genbase Biotechnology Co. Ltd, which was established in 2015 to focus on developing new therapeutic drugs, including cell therapies, gene therapies and therapeutic antibodies. Prior to that, Dr. Jijun Yuan spent six years at Shanghai Hengrui Pharmaceutical Co. as the associate director in charge of the biological division. He has been involved in more than 30 drug discovery programs, including oncology, diabetes and cardiovascular therapeutic drugs.
Dr. Jijun Yuan holds a PhD degree in molecular biology from Ohio State University and worked as postdoctoral researcher at University of California Los Angeles.
President and Chief Executive Officer
Asclepius Technology Company Group ( ATCG Corp )
Dr. Huashun Li graduated from the Second Military Medical University in Shanghai in 1986, got his master degree from the PLA General Hospital in Beijing in 1989, was a visiting scholar in Johns Hopkins University between 1991 to 1994, received his PhD from Washington University School of Medicine in St. Louis, Missouri, USA in 1999, did postdoctoral research at UCSF between 1999 to 2005, was an assistant professor in Developmental Neurobiology Program in the Institute of Molecular Medicine and Genetics at the Medical College of Georgia, Augusta, Georgia, USA between 2005 and 2007, was a founding director of West China Developmental & Stem Cell Institute at Sichuan University between 2007 and 2012, and became the funding director of SARITE Center for Stem Cell Engineering Translational Medicine in Shanghai East Hospital Tongji University School of Medicine between 2013 and 2015. Dr. Li is the founder of ATCG Corp. and has been the president & CEO of the company focusing on developing innovative drugs to treat cancer and inflammation since 2013.
Chief Medical Officer
Exuma Biotechnology, F1 Oncology International Affiliate
Wendy Li, MD, is Chief Medical Officer of Exuma Biotechnology, F1 Oncology International Affiliate. With ten years of clinical practice and over twenty years of experience in providing medical and scientific leadership in clinical research in Oncology and other therapeutics areas, with previous experience at Genentech, Sanofi, and Pfizer. For the last couple of years, Dr. Li has been Medical Head/Vice President of Clinical Development for an EU Biotechnology start up, she has provided medical and clinical guidance in the review and evaluation of Immuno-Oncology products. Prior to this position she held a VP/CMO position with Sihuan Pharma/Co-Xuanzhu Pharma. She has provided leadership on global early and late stage clinical studies, responded to FDA/CFDA and related agencies, and advised clinical, marketing, regulatory, and pharmacovigilance teams. Dr. Li received her MD from the Sun Yat-Sen University of Medical Studies in China.
Senior Director, Head of Business Development and External Alliances for Greater China
Joey Zhou graduated from Nanjing Medical School and West-China Medical Center with bachelor and master’s degree in clinical medicine. Later he got his Ph.D majored in Pharmaceutical & Therapeutics from the Trinity College Dublin and MBA from Michael Smurfit Business School in University College Dublin. Dr.Zhou used to work as a senior research scientists in the St James Hospital. After Dr.Zhou came back China in 2010, he worked in several pharmaceutical companies in charge of the business development, products license-in and out, and external collaboration.
Joey is now the head of business development of external alliances for Greater China in Harbour BioMed, his main responsibilities include license-out HBM’s transgenic mice platform, license-in and out assets and help HBM to build-up strategic collaboration with China based companies.
VP of Cell Therapy and Antibody Research
Luye Boston R&D LLC
Li Zhou, PhD, VP of Cell Therapy and Antibody Research at Luye Boston. His was VP of CAR-T Cell Therapy at Livzon Mabpharm in Zhuhai Guangdong. His team established the lentivector and CAR-T GMP manufacturing platforms and advanced the first internal CAR-T program into the IND enabling clinical study. Before this, he was VP of Cell Engineering at TxCell (now is Sangamo therapeutics) in France. He led the team quickly built a diverse CAR-Treg product pipeline for treating autoimmune disease and organ transplant rejection. His team helped advancing the first-ever CAR-Treg clinical trial for prevention of organ transplant rejection. As CSO and Director of Research at ZMKS international Cancer Therapy Biotechnologies Co., he pioneered the effort in engineering the armed CAR-T cells that can secrete bispecific checkpoint inhibitor antibodies. Prior to this, he was investigator III/lab head in Novartis Biologics Center in Cambridge working on developing bispecific antibody therapeutics, and CAR-T therapies. He led a number of CAR-T programs including CD22 CAR-T, bispecific CD19/CD22 CAR-T to treat antigen negative relapse in blood cancers, Mesothelin CAR-T against solid tumors, as well as on-switch regulatable CAR-T program. Dr Zhou received his BS and MS from Nankai University and PhD from Beijing University.
Chairman & Chief Scientific Officer
Founder and CSO, Hebei Senlang Biotechnology Co. Ltd
Adjunct Professor of Second Hospital of Hebei Medical University
• 2011–2016 Postdoc & Scientist, Fred Hutchinson Cancer Research Center, Seattle
• 2006-2010 PhD in Immunology, University of Wuerzburg, Germany
• 2003-2006 M.Sc in Immunology, Peking Union Medical College, China
• Gene modified adoptive T cell therapy
• In vitro expansion and gene editing of Hematopoietic stem cells
• Transplant Immunology